Phaseline

Companies › Lexeo Therapeutics

Lexeo Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Cardiovascular, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LX2006
Adeno-associated viral vector (AAVrh.10) delivering the human frataxin (FXN) gene to cardi
FXNPhase 2Friedreich AtaxiaSep 2029
LX2020
Adeno-associated viral vector (AAVrh.10) encoding human Plakophilin-2 (PKP2) gene
PKP2Phase 1Arrhythmogenic CardiomyopathyDec 2026
LX1001 (AAVrh.10hAPOE2)
Gene therapy delivering human APOE2 via adeno-associated virus serotype rhesus 10
APOEPhase 1Alzheimer DiseaseNov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06109181LX2020Phase 1Arrhythmogenic CardiomyopathyCardiovascularDec 2026
NCT05400330LX1001 (AAVrh.10hAPOE2)Phase 1Alzheimer DiseaseNeurologyNov 2028
NCT05445323LX2006Phase 1Friedreich AtaxiaCardiovascularSep 2029
NCT07721025LX2006Phase 2Friedreich AtaxiaCardiovascularJun 2032

From the company's SEC filings

Cash and short-term investments of $234m on 2026-06-30; operating cash outflow about $79m a year; runway about 36 months at that burn, to Jun 2029; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

FXN (1) APOE (1) PKP2 (1)

Companies with the same targets

Larimar Therapeutics Solid Biosciences Tenaya Therapeutics Rocket Pharmaceuticals

Companies built like this

Rocket Pharmaceuticals Beijing Inno Medicine Nectero Medical Rohto Pharmaceutical Solid Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.